Study Affirms Shorter Regimens for Drug-Resistant Tuberculosis

Two short-course bedaquiline-containing regimens are promising treatment options for multidrug-resistant tuberculosis.

Related Keywords

Georgia ,United States ,Mongolia ,United Kingdom ,Texas ,University Of Cape Town ,Western Cape ,South Africa ,Moldova ,Cape Town ,Uganda ,Baylor College Of Medicine ,Ethiopia ,London ,City Of ,Germany ,India ,London School ,Houston ,German ,Keertan Dheda ,Christoph Lange ,Ruth Goodall ,Janssen Research ,University College London ,World Health Organization ,European Commission ,German Center ,Infection Research ,Research Council Clinical Trials Unit ,London School Of Hygiene ,African Medical Research Council ,Medical Research Council Clinical Trials Unit ,Standard Treatment Regimen ,Anti Tuberculosis Drugs ,Patients With ,Shorter Treatment ,Better Outcomes ,Multidrug Resistant Tuberculosis ,Tropical Medicine ,Baylor College ,Texas Children ,South African Medical Research Council ,Tuberculosis Tb ,Tuberculosis ,Tb ,Drug Resistant Tb ,Drug Resistant Tuberculosis ,Hototoxicity ,Otolaryngology ,Nt Ears ,Nose ,Throat ,Hearing Loss ,Hospitals ,United Kingdom Site Content ,Boards ,Smle ,Europe ,European ,Health Facilities ,Pandemic ,Stress ,Toxicology ,Coronavirus ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc4 ,